Table 1.
Characteristics of included studies: psoriasis and comorbidities.
Study | Region | Study period | Data sources | Mean age, (y); Female (%) |
N° of psoriatic patients |
N° of Control |
Specific comorbidities | NOS | |||
---|---|---|---|---|---|---|---|---|---|---|---|
Psoriasis | Control | All | Comorbidities | All | Comorbidities | ||||||
Ahlehoff O, 201130 | Danish | 2002–2006 | The Danish National Patient Register | 69.5 (12.1); 36.58 | 70.6 (13.5); 38.72 | 462 | 199 | 48935 | 20356 | CVD, KD, PD | 6 |
Ahlehoff O, 201231 | Danish | 1997.01–2006.12 | The Danish National Patient Register | 46.1 ± 16.9; 49.72 | 43.7 ± 19.7; 49.03 | 39558 | 530 | 4478926 | 55660 | CVD, KD, CD, PD | 7 |
Armstrong AW, 201332 | US | 2004–2009 | University of California Davis | 53 (40‒63); 59.19 | 53 (40‒63); 51.11 | 2078 | 1776 | 6234 | 3616 | CVD, CD, PD | 6 |
Charlton R, 201833 | UK | 1998.01–2014.12 | The UK Clinical Practice Research Datalink | 49 (39‒59); 50.95 | 49 (39‒59); 50.95 | 27132 | 8444 | 27132 | 7051 | CVD, CD | 7 |
Chiang CH, 201134 | Taiwan | Before 2007 | Longitudinal Health Insurance Database 2007 | 45.3 ± 17.4; 43.69 | 43.5 ± 17.4; 22.14 | 2783 | 1066 | 13910 | 5145 | CVD, KD | 6 |
Feldman SR, 201535 | US | 2007.01–2012.03 | The OptumHealth Reporting and Insights claims database | 47.62; 44.50 | 47.62; 44.50 | 5492 | 881 | 5492 | 499 | KD, CD, PD, LD | 7 |
Khalid U, 201536 | Danish | 1997.01–2011.12 | The Danish National Patient Register | 43.3 (15.8); 51.48 | 41.9 (19.9); 5 0.71 | 70665 | 1292 | 5036959 | 105321 | CVD, KD, PD | 7 |
aLee S, 201737 | US | 2010.11–2015.10 | The US Department of Defense population | 48.1; 51.84 | 48.1; 51.84 | 7249 | 2932 | 72490 | 22367 | CVD, CD | 7 |
Min C, 201926 | Korean | 2002‒2013 | The Korean National Health Insurance Service-National Sample Cohort | NR; 43.32 | NR; 43.32 | 11071 | 5187 | 44284 | 20298 | CVD, CD | 7 |
Prasada S, 202029 | US | 2000.01–2019.01 | The Northwestern Medicine Enterprise Data Warehouse | 49.72 (15.95); 51.71 | 48.60 (16.65); 57.34 | 5365 | 1536 | 19358 | 5241 | CVD, KD | 7 |
Schell C, 201538 | German | NR | Eberhard Karls University Tübingen | 48.3 ± 15.6; 43.33 | 49.1 ± 18.6; 60.00 | 300 | 158 | 300 | 150 | CVD, KD, PD, LD | 6 |
Tollefson MM, 201828 | US | 2004.01–2013.12 | Optum Laboratories Data Warehouse | 12.0 (4.4); 53.52 | 12.0 (4.4); 53.52 | 29957 | 1200 | 29957 | 646 | CVD, LD | 8 |
Vena GA, 201039 | Italy | 2001‒2005 | The Health Search/Thales Database | 52.5 (16.5); 47.41 | 52.4 (16.4); 52.59 | 3516 | 399 | 17580 | 1425 | CVD, PD | 6 |
Yang YW, 201127 | Taiwan | 2006.01–2007.12 | Longitudinal Health Insurance Database2000 | NR, >18; 32.58 | NR, >18; 67.42 | 1685 | 1471 | 5055 | 3651 | CVD, KD, CD, PD, LD | 8 |
Yeung H, 201340 | UK | NR | The Health Improvement Network | 46 (37‒55); 49.43 | 46 (36‒55); 52.91 | 9035 | 1945 | 90350 | 17502 | CVD, KD, CD, PD, LD | 6 |
NR, Not Reported; NOS, Newcastle–Ottawa Quality Assessment Scale; CVD, Cardiovascular Disease; CD, Cerebrovascular Disease; KD, Kidney Disease; PD, Pulmonary Disease; LD, Liver Disease; US, United States; UK, United Kingdom.
The data of study included Psoriatic arthritis.37